Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study.

ABSTRACT:

Background

Linezolid is recommended for treating drug-resistant TB. Adverse events are a concern to prescribers but have not been systematically studied at the standard dose, and the relationship between linezolid exposure and clinical toxicity is not completely elucidated.

Patients and methods

We conducted an observational cohort study to describe the incidence and determinants of linezolid toxicity, and to determine a drug exposure threshold for toxicity, among patients with rifampicin-resistant TB in South Africa. Linezolid exposures were estimated from a population pharmacokinetic model. Mixed-effects modelling was used to analyse toxicity outcomes.

Results

One hundred and fifty-one participants, 63% HIV positive, were enrolled and followed for a median of 86 week

SUBMITTER: Wasserman S 

PROVIDER: S-EPMC7612559 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature